LVM Capital Management Ltd. MI lowered its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 116,498 shares of the company’s stock after selling 1,325 shares during the quarter. Johnson & Johnson comprises 3.7% of LVM Capital Management Ltd. MI’s portfolio, making the stock its 8th largest position. LVM Capital Management Ltd. MI’s holdings in Johnson & Johnson were worth $16,277,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. grew its stake in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC grew its stake in Johnson & Johnson by 717.9% during the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock valued at $495,837,000 after purchasing an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Johnson & Johnson by 47.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after purchasing an additional 2,581,562 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in Johnson & Johnson by 6,715.9% during the 3rd quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after purchasing an additional 2,534,918 shares in the last quarter. Institutional investors and hedge funds own 67.21% of the company’s stock.
A number of equities research analysts have weighed in on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price objective for the company in a research note on Tuesday, January 23rd. Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th. Wells Fargo reaffirmed an “outperform” rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $146.06.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $127.38 on Friday. The stock has a market capitalization of $351,969.94, a P/E ratio of 17.97, a P/E/G ratio of 2.09 and a beta of 0.77. Johnson & Johnson has a 1-year low of $120.95 and a 1-year high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to the consensus estimate of $20.08 billion. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the business posted $1.58 EPS. analysts forecast that Johnson & Johnson will post 8.11 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 2.64%. The ex-dividend date of this dividend was Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Shares Sold by LVM Capital Management Ltd. MI” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/03/23/johnson-johnson-jnj-shares-sold-by-lvm-capital-management-ltd-mi.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.